PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT01933672
- Locations
- πΊπΈ
Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States
πΊπΈAvail Clinical Research, LLC, DeLand, Florida, United States
πΊπΈHigh Point Clinical Trials Center, LLC, High Point, North Carolina, United States
Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9968
- Registration Number
- NCT01932372
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT01927341
- Locations
- πΊπΈ
University of California at Los Angeles Dept of Onc, Los Angeles, California, United States
πΊπΈMemorial Sloan Kettering Cancer Center Oncology Dept, New York, New York, United States
πͺπΈPfizer Investigative Site, Barcelona, Catalunya, Spain
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT01925274
- Locations
- πΊπΈ
Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States
πΊπΈSiteman Cancer Center - St Peters, Saint Peters, Missouri, United States
πΊπΈKadlec Medical Center, Richland, Washington, United States
A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01924650
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: 100 mg PF-05231023Other: Placebo
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT01923389
- Locations
- πΊπΈ
Pfizer Investigational Site, Orlando, Florida, United States
A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT01920399
- Locations
- π¨π³
Research Site, Shanghai, China
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
- Conditions
- Neoplasm
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT01920061
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMedical University of South Carolina/ University Hospital, Charleston, South Carolina, United States
πΊπΈMUSC Health East Cooper, Mount Pleasant, South Carolina, United States
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT01919996
- Locations
- πΊπΈ
Infant Welfare Society of Chicago, Chicago, Illinois, United States
πΊπΈMartel Eye Medical Group, Rancho Cordova, California, United States
πΊπΈAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT01918176
- Locations
- πΊπΈ
Pfizer Investigational Site, South Miami, Florida, United States